15.70
3.27%
-0.53
After Hours:
15.70
Macrogenics Inc stock is currently priced at $15.70, with a 24-hour trading volume of 510.23K.
It has seen a -3.27% decreased in the last 24 hours and a +8.43% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $16.14 pivot point. If it approaches the $15.69 support level, significant changes may occur.
Previous Close:
$16.23
Open:
$16.16
24h Volume:
510.23K
Market Cap:
$982.20M
Revenue:
$56.91M
Net Income/Loss:
$-9.06M
P/E Ratio:
130.83
EPS:
0.12
Net Cash Flow:
$-79.97M
1W Performance:
-2.48%
1M Performance:
+8.43%
6M Performance:
+216.53%
1Y Performance:
+134.33%
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 Medical Center Drive, Rockville, MD
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Feb-04-22 | Initiated | SMBC Nikko | Outperform |
Nov-17-21 | Resumed | Guggenheim | Buy |
Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
Oct-15-21 | Resumed | BTIG Research | Buy |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
Dec-22-20 | Resumed | H.C. Wainwright | Buy |
Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
May-26-20 | Reiterated | H.C. Wainwright | Buy |
Mar-04-20 | Initiated | Barclays | Underweight |
Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Nov-20-19 | Resumed | Guggenheim | Neutral |
May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
Apr-12-19 | Initiated | Guggenheim | Neutral |
Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
Sep-10-18 | Resumed | BTIG Research | Buy |
May-31-18 | Initiated | Evercore ISI | Outperform |
Mar-05-18 | Initiated | H.C. Wainwright | Buy |
Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
The Latest Analyst Ratings For Macrogenics
Benzinga
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Benzinga
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
GlobeNewswire Inc.
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
The Motley Fool
Macrogenics Inc Stock (MGNX) Financials Data
Macrogenics Inc (MGNX) Revenue 2024
MGNX reported a revenue (TTM) of $56.91 million for the quarter ending December 31, 2023, a -61.96% decline year-over-year.
Macrogenics Inc (MGNX) Net Income 2024
MGNX net income (TTM) was -$9.06 million for the quarter ending December 31, 2023, a +92.44% increase year-over-year.
Macrogenics Inc (MGNX) Cash Flow 2024
MGNX recorded a free cash flow (TTM) of -$79.97 million for the quarter ending December 31, 2023, a +11.72% increase year-over-year.
Macrogenics Inc (MGNX) Earnings per Share 2024
MGNX earnings per share (TTM) was -$0.16 for the quarter ending December 31, 2023, a +91.75% growth year-over-year.
About Macrogenics Inc
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, and autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company also has a translational research agreement with NanoString Technologies, Inc. for the identification and development of biomarkers for MGD013 program. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):